对认知正常和轻度认知障碍亚型的数据驱动分类预测了NACC数据集中的进展
Emily C Edmonds1,2, Kelsey R Thomas3,4, Steven Z Rapcsak1,2,5
1Banner Alzheimer's Institute, Tucson, Arizona, USA.
概括
数据驱动的方法确定了轻度认知障碍 (MCI) 和正常认知的不同亚型,提供比传统诊断更精确的痴呆风险预测.
科学领域:
- 神经科学是一个神经科学.
- 认知科学 认知科学
- 老年学是一门学科.
背景情况:
- 对于轻度认知障碍 (MCI) 的常规诊断方法可能无法完全捕捉认知衰退的异质性.
- 识别特定的MCI亚型对于了解痴呆症风险因素和进展至关重要.
研究的目的:
- 将数据驱动的集群分析应用于神经心理学数据,以识别不同的MCI亚型.
- 将数据驱动方法的痴呆风险预测准确度与传统诊断进行比较.
- 探索正常认知群体内的认知异质性.
主要方法:
- 集群分析是在国家阿尔茨海默氏症协调中心 (NACC) 统一数据集中的26,255名参与者的神经心理数据上进行的.
- 使用生存分析来检查MCI或痴呆症的进展在已识别的集群中.
- 分析包括一般队列和16005名具有正常认知能力的参与者的子样本.
主要成果:
- 确定了五个不同的集群:最佳CN (oCN),典型CN (tCN),无情MCI (aMCI),混合MCI-轻度 (mMCI-轻度) 和混合MCI-重度 (mMCI-重度),痴呆症进展率不同.
- 数据驱动的方法发现了更多的MCI病例,而不是共识诊断.
- 在正常认知子样本中,出现了五个集群 (高全部,低WM,低记忆,aMCI,MMCI) 具有不同的进展率.
结论:
- 数据驱动的神经心理方法提供了比共识诊断更精确的痴呆风险分层.
- 这些方法在MCI和正常认知组中都显示出显著的认知异质性.
- 这些发现突显了高级分析技术在认知衰老研究中对个性化风险评估的有用性.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.集群分析集群分析集群分析认知子类型 认知子类型痴呆症 痴呆症是一种痴呆症.轻度的认知障碍 轻度的认知障碍神经心理学神经心理学临床前阿尔茨海默氏症疾病微妙的认知能力下降.更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.3K
相关概念视频
01:30Cognitive Development During Adulthood
96
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
96
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113